![X Highlights Back-To-School Marketing Opportunities [Infographic]](https://imgproxy.divecdn.com/dM1TxaOzbLu_kb9YjLpd7P_E_B_FkFsuKp2uSGPS5i8/g:ce/rs:fit:770:435/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS94X2JhY2tfdG9fc2Nob29sMi5wbmc=.webp)
Why Novo Nordisk Stock Pumped Higher on Thursday
Positive news from the laboratory was the wind beneath the wings of Novo Nordisk (NYSE: NVO) stock on Thursday. The Denmark-based pharmaceutical company, famed for its Ozempic and Wegovy drugs, saw its share price improve by nearly 3% on the day after it reported the results of a late-stage clinical trial. That rise easily bettered the 0.4% gain of the S&P 500 index.That news concerned amycretin, an investigational weight-loss drug that would represent a step up from the highly popular Wegovy. Novo Nordisk reported that it is advancing amycretin to a phase 3 study. Image source: Getty Images.Continue reading
Positive news from the laboratory was the wind beneath the wings of Novo Nordisk (NYSE: NVO) stock on Thursday. The Denmark-based pharmaceutical company, famed for its Ozempic and Wegovy drugs, saw its share price improve by nearly 3% on the day after it reported the results of a late-stage clinical trial. That rise easily bettered the 0.4% gain of the S&P 500 index.
That news concerned amycretin, an investigational weight-loss drug that would represent a step up from the highly popular Wegovy. Novo Nordisk reported that it is advancing amycretin to a phase 3 study.
Image source: Getty Images.
